These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 32148857)
21. Muscarinic acetylcholine M Liu L; Huang Y; Huang Q; Zhao Z; Yu J; Wang L Neuropharmacology; 2017 May; 117():376-386. PubMed ID: 28257887 [TBL] [Abstract][Full Text] [Related]
22. In Silico Analysis of Binding Interaction of Mamba Toxins with M4 and M2 Muscarinic Acetylcholine Receptors for Therapeutic Use in Alzheimer's Disease. Waqar M; Kamal MA; Batool S CNS Neurol Disord Drug Targets; 2015; 14(8):1031-40. PubMed ID: 26295818 [TBL] [Abstract][Full Text] [Related]
23. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline. Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428 [TBL] [Abstract][Full Text] [Related]
24. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishankar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK Neuropsychopharmacology; 2014 Jun; 39(7):1578-93. PubMed ID: 24442096 [TBL] [Abstract][Full Text] [Related]
25. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561 [TBL] [Abstract][Full Text] [Related]
26. Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres. Yang Q; Lachapelle EA; Kablaoui NM; Webb D; Popiolek M; Grimwood S; Kozak R; O'Connor RE; Lazzaro JT; Butler CR; Zhang L ACS Med Chem Lett; 2019 Jun; 10(6):941-948. PubMed ID: 31223452 [TBL] [Abstract][Full Text] [Related]
27. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722 [TBL] [Abstract][Full Text] [Related]
28. Regulation of signal transduction at M2 muscarinic receptor. Krejcí A; Michal P; Jakubík J; Rícný J; Dolezal V Physiol Res; 2004; 53 Suppl 1():S131-40. PubMed ID: 15119944 [TBL] [Abstract][Full Text] [Related]
29. Structural insights into the subtype-selective antagonist binding to the M Suno R; Lee S; Maeda S; Yasuda S; Yamashita K; Hirata K; Horita S; Tawaramoto MS; Tsujimoto H; Murata T; Kinoshita M; Yamamoto M; Kobilka BK; Vaidehi N; Iwata S; Kobayashi T Nat Chem Biol; 2018 Dec; 14(12):1150-1158. PubMed ID: 30420692 [TBL] [Abstract][Full Text] [Related]
30. Live-cell microscopy or fluorescence anisotropy with budded baculoviruses-which way to go with measuring ligand binding to M Tahk MJ; Torp J; Ali MAS; Fishman D; Parts L; Grätz L; Müller C; Keller M; Veiksina S; Laasfeld T; Rinken A Open Biol; 2022 Jun; 12(6):220019. PubMed ID: 35674179 [TBL] [Abstract][Full Text] [Related]
31. Distinct internalization of M2 muscarinic acetylcholine receptors confers selective and long-lasting desensitization of signaling to phospholipase C. Krudewig R; Langer B; Vögler O; Markschies N; Erl M; Jakobs KH; van Koppen CJ J Neurochem; 2000 Apr; 74(4):1721-30. PubMed ID: 10737631 [TBL] [Abstract][Full Text] [Related]
32. Biochemical characterization of a heterotrimeric G(i)-protein activator peptide designed from the junction between the intracellular third loop and sixth transmembrane helix in the m4 muscarinic acetylcholine receptor. Terawaki S; Matsubayashi R; Hara K; Onozuka T; Kohno T; Wakamatsu K Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):64-9. PubMed ID: 25986737 [TBL] [Abstract][Full Text] [Related]
38. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Teal LB; Gould RW; Felts AS; Jones CK Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251 [TBL] [Abstract][Full Text] [Related]
39. Structural Characteristics of the Allosteric Binding Site Represent a Key to Subtype Selective Modulators of Muscarinic Acetylcholine Receptors. Bermudez M; Rakers C; Wolber G Mol Inform; 2015 Aug; 34(8):526-30. PubMed ID: 27490498 [TBL] [Abstract][Full Text] [Related]